729 completed, 124 terminated, 107 unknown, 55 recruiting. 300 Phase 2, 226 Phase 1, 213 Not applicable, 147 Phase 3, 62 Phase 4.
Follow Alzheimer's Disease: new trials by email Literature Review of Alzheimer's Disease trials Research Report on Alzheimer's Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Advancing Ethical Goals In Society Trial ACP Counselor Video Program - Advance Care Planning, Dementia | Not applicable | Not yet recruiting | Tufts Medical Center | 12174 | 2027-03-01 | 2026-09-17 |
| Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease Comfy Acupressure for the Elderly, Least acupressure control - Alzheimer's Disease | Not applicable | Not yet recruiting | The University of Hong Kong | 188 | 2027-01-01 | 2026-08-24 |
| Repurposing a Combination Antiretroviral Drug Therapy to Target Retrotransposons and Treat Early Alzheimer's Disease Emtricitabine and tenofovir disoproxil fumarate combination, Placebo - Alzheimer's Disease | Phase 1 | Not yet recruiting | Brigham and Women's Hospital | 20 | 2026-12-01 | 2026-08-31 |
| Electroconvulsive Therapy for Treatment of Alzheimer´s Disease Thymatron IV device (Somatics) - Alzheimer's Disease | Not applicable | Not yet recruiting | Central Institute of Mental Health, Mannheim | 15 | 2026-12-01 | 2026-09-08 |
| A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease Trontinemab, Placebo - Alzheimer's Disease | Phase 3 | Recruiting | Hoffmann-La Roche | 1600 | 2026-11-30 | 2026-10-13 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR 3201 Injection in Healthy Participants SHR 3201 Injection, SHR 3201 Placebo. - Alzheimer's Disease | Phase 1 | Not yet recruiting | Beijing Suncadia Pharmaceuticals Co., Ltd | 50 | 2026-11-01 | 2026-10-22 |
| Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease RO7568282, Placebo - Alzheimer's Disease | Phase 2 | Not yet recruiting | Hoffmann-La Roche | 450 | 2026-10-31 | 2026-10-07 |
| An Observational Study of LEQEMBI in Routine Clinical Practice in Taiwan No Intervention - Alzheimer's Disease | Not yet recruiting | Eisai Taiwan Inc. | 100 | 2026-10-29 | 2026-10-09 | |
| Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin Psilocybin, Cognitive Training - Alzheimer's Disease | Phase 2 | Recruiting | National Institute on Aging (NIA) | 200 | 2026-10-27 | 2026-10-22 |
| A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects T3D-959, Placebo Comparator - Alzheimer's Disease | Phase 2 / Phase 3 | Not yet recruiting | T3D Therapeutics, Inc. | 376 | 2026-10-26 | 2025-05-09 |
| Choose Myself (Before) Losing Myself CYOA booklet - Dementia (Diagnosis), Mild Cognitive Impairment | Not applicable | Recruiting | The Cleveland Clinic | 25 | 2026-10-09 | 2026-10-22 |
| Cognition and Affective Research in China Neurodegenerative Disease, Dementia | Not yet recruiting | Xuanwu Hospital, Beijing | 3000 | 2026-10-01 | 2026-09-22 | |
| Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a Background Acetylcholinesterase Inhibitor NBI-1117567, Placebo - Alzheimer's Disease | Phase 2 | Not yet recruiting | Neurocrine Biosciences | 135 | 2026-10-01 | 2026-09-22 |
| Validation Study of the ExéSem Battery Designed to Differentiate the Contribution of Executive Functions in Semantic Disorders ExéSem cognitive battery - Alzheimer's Disease, Vascular Neurocognitive Disorder | Not yet recruiting | Hospices Civils de Lyon | 140 | 2026-09-09 | 2026-05-07 | |
| Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study Photobiomodulation - Alzheimer's Disease | Not applicable | Recruiting | Cedars-Sinai Medical Center | 45 | 2026-09-01 | 2026-10-13 |
| A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration BMS-986446 - Alzheimer's Disease, Healthy Participants | Phase 1 | Recruiting | Bristol-Myers Squibb | 84 | 2026-08-21 | 2026-09-24 |
| Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD. [18F]-APN-1607 - Alzheimer's Disease | Phase 3 | Recruiting | JYAMS PET Research & Development Limited | 12 | 2026-08-15 | 2026-08-17 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's Disease DNL921, Placebo - Alzheimer's Disease, Healthy Participants | Phase 1 | Recruiting | Denali Therapeutics Inc. | 178 | 2026-08-07 | 2026-08-20 |
| A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease SAR448851, Placebo - Dementia, Alzheimer's Type, Alzheimer's Disease | Phase 2 | Recruiting | Sanofi | 160 | 2026-07-28 | 2026-09-22 |
| Deep Cervical Lymphovenous Anastomosis for Moderate Alzheimer's Disease Deep cervical lymphovenous anastomosis (LVA), Routine Treatment - Alzheimer's Disease | Not applicable | Not yet recruiting | Southwest Hospital, China | 296 | 2026-07-01 | 2026-06-22 |
Showing 20 of 1081. Sign in to see all of them.
Alzheimer Disease (1081) · Dementia (233) · Cognitive Dysfunction (155) · Memory Disorders (36) · Neurodegenerative Diseases (31) · Psychomotor Agitation (25) · Parkinson Disease (21) · Dementia, Vascular (20) · Plaque, Amyloid (20) · Brain Diseases (19) · Central Nervous System Diseases (19) · Mental Disorders (19) · Depression (17) · Frontotemporal Dementia (16) · Nervous System Diseases (16)
Tauopathies (1073) · Neurocognitive Disorders (1071) · Nervous System Diseases (1065) · Brain Diseases (1062) · Central Nervous System Diseases (1062) · Mental Disorders (1062) · Neurodegenerative Diseases (1050) · Dementia (848) · Cognition Disorders (161) · Pathological Conditions, Signs and Symptoms (149) · Neurologic Manifestations (106) · Signs and Symptoms (105) · Neurobehavioral Manifestations (90) · Behavior (64) · Nutritional and Metabolic Diseases (47)
Donepezil (58) · Memantine (25) · florbetapir (24) · Rivastigmine (15) · latrepirdine (15) · Galantamine (14) · Magnetic Resonance Spectroscopy (12) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (10) · 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole (9) · Exercise (9) · aducanumab (9) · solanezumab (9) · 3-benzenesulfonyl-8-piperazin-1-ylquinoline (8) · flutemetamol (8) · ABT-126 (7)
Pfizer (34) · GlaxoSmithKline (29) · Avid Radiopharmaceuticals (27) · Eli Lilly and Company (26) · Merck Sharp & Dohme LLC (25) · National Institute on Aging (NIA) (19) · AstraZeneca (16) · Eisai Inc. (15) · Hoffmann-La Roche (13) · Novartis Pharmaceuticals (13) · Biogen (11) · Bristol-Myers Squibb (10) · Chang Gung Memorial Hospital (10) · H. Lundbeck A/S (10) · Novartis (10)
United States (595) · France (132) · Canada (129) · United Kingdom (107) · Spain (97) · Germany (96) · South Korea (85) · Australia (74) · Italy (66) · Sweden (63) · Japan (58) · China (53) · Poland (52) · Netherlands (42) · Taiwan (39)
Mariana Figueiro, PhD (6) · Laura Gault, MD (5) · Paul Aisen, MD (5) · Suzanne Craft, PhD (5) · Jeffrey Burns, MD (4)
PMID 39498781, PMID 40603145, PMID 39800465, PMID 26120369, PMID 26402769, PMID 27807285, PMID 29318278, PMID 30474567, PMID 31193334, PMID 33189083, PMID 36641609, PMID 36946603, PMID 39350369, PMID 39513754, PMID 40049590, PMID 40681915, PMID 41220869, PMID 41533472, PMID 41961243, PMID 42841310, PMID 22749065, PMID 24450890, PMID 24450891, PMID 25125457, PMID 25669746, PMID 25789616, PMID 26208959, PMID 26925577, PMID 26967214, PMID 27756421, PMID 27871675, PMID 28269765, PMID 28487349, PMID 29615123, PMID 29854923, PMID 29854934, PMID 29854935, PMID 30052328, PMID 30412493, PMID 30902090, PMID 31708380, PMID 31831056, PMID 31969177, PMID 33597012, PMID 33974419, PMID 34521461, PMID 34807243, PMID 35384522, PMID 36121669, PMID 36600109
2009 (9), 2015 (8), 2025 (7), 2014 (5), 2016 (5), 2017 (4), 1RC2AG036535 (3), 2008 (3), 2018 (3), 2023 (3), 2005 (2), K23AG052633 (2), P50AG005136 (2), R01AG034157 (2), 1RC2AG036535-01 (1)